Get the Stockscreener App
0.169
1.20%
0.002
After Hours:
.17
0.001
+0.59%
Glycomimetics Inc stock is traded at $0.169, with a volume of 454.21K.
It is up +1.20% in the last 24 hours and down -4.14% over the past month.
GlycoMimetics Inc is a clinical-stage biotechnology company. It is focused on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. Glycomimetics are molecules that mimic the structure of carbohydrates involved in important biological processes. Using expertise in carbohydrate chemistry and knowledge of carbohydrate biology, the company is developing a pipeline of proprietary glycomimetics that may inhibit disease-related functions of carbohydrates, such as the roles it play in inflammation, cancer, and infection.
See More
Previous Close:
$0.167
Open:
$0.165
24h Volume:
454.21K
Relative Volume:
0.38
Market Cap:
$10.62M
Revenue:
$1.16M
Net Income/Loss:
$-37.28M
P/E Ratio:
-0.26
EPS:
-0.65
Net Cash Flow:
$-33.81M
1W Performance:
+2.74%
1M Performance:
-4.14%
6M Performance:
-94.37%
1Y Performance:
-88.73%
1-Day Range:
$0.162
$0.1715
1-Week Range:
$0.159
$0.1715
52-Week Range:
$0.155
$3.5299
Glycomimetics Inc Stock (GLYC) Company Profile
Name
Glycomimetics Inc
Sector
Industry
Phone
240-243-1201
Address
9708 MEDICAL CENTER DRIVE, ROCKVILLE, MD
Glycomimetics Inc Stock (GLYC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-12-21 | Upgrade | Jefferies | Hold → Buy |
| Nov-14-19 | Initiated | ROTH Capital | Buy |
| Aug-05-19 | Downgrade | Jefferies | Buy → Hold |
| Aug-05-19 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Aug-05-19 | Downgrade | SunTrust | Buy → Hold |
| Apr-12-19 | Initiated | Piper Jaffray | Overweight |
| Dec-18-18 | Initiated | H.C. Wainwright | Buy |
| Jul-26-16 | Initiated | SunTrust | Buy |
| Mar-17-15 | Reiterated | Stifel | Buy |
View All
Glycomimetics Inc Stock (GLYC) Latest News
GlycoMimetics Inc [GLYC] Records 50-Day SMA of $0.1928 - Knox Daily
GLYC’s Stock Market Pendulum: Swinging Between Gains and Losses - The InvestChronicle
GlycoMimetics Inc [GLYC] Stock sold by Insider Invus Public Equities, L.P. for $50009.0 - Knox Daily
Capital One Initiates Coverage of GlycoMimetics (GLYC) with Overweight Recommendation - MSN
Market Insights: GlycoMimetics Inc (GLYC)’s Notable Drop of -0.18, Closing at 0.16 - The Dwinnex
Is GlycoMimetics Inc (GLYC) a threat to investors? - US Post News
GlycoMimetics Inc [NASDAQ: GLYC] Sees Decrease in Stock Value - Knox Daily
Analytical Lens: Exploring GlycoMimetics Inc (GLYC)’s Financial Story Through Ratios - The Dwinnex
India Glycols receives revision in credit rating from CARE - Business Standard
CARE Ratings affirms 'A-' rating of India Glycols with 'stable' outlook - Business Standard
StockNews.com Initiates Coverage on GlycoMimetics (NASDAQ:GLYC) - Defense World
Glycomine Receives FDA Fast Track Designation for GLM101 for the Treatment of PMM2-CDG - BioSpace
Galmed Pharmaceuticals Soars Nearly 500% Amid Nasdaq Compliance and Short Squeeze - TipRanks
Galmed Pharmaceuticals Surges 400%: What's Behind the Explosion? - MarketBeat
GlycoMimetics Inc [GLYC] Investment Appeal on the Rise - Knox Daily
Short Interest in GlycoMimetics, Inc. (NASDAQ:GLYC) Decreases By 16.5% - Defense World
TD Cowen’s latest rating for GLYC stock - Knox Daily
Closing Figures: GlycoMimetics Inc (GLYC)’s Negative Finish at 0.16, Down -2.82 - The Dwinnex
GlycoMimetics (NASDAQ:GLYC) Coverage Initiated at StockNews.com - Defense World
Wall Street analysts’ outlook for GlycoMimetics Inc (GLYC) - SETE News
GLYC’s Debt-to-Equity Ratio at 0.02: What It Means for GlycoMimetics Inc’s Future - The InvestChronicle
GlycoMimetics stock plunges to 52-week low of $0.16 - Investing.com
GlycoMimetics stock plunges to 52-week low of $0.16 By Investing.com - Investing.com UK
Trading Day Review: GlycoMimetics Inc (GLYC) Gains Momentum, Closing at 0.18 - The Dwinnex
GlycoMimetics Inc (GLYC) did well last session? - US Post News
GlycoMimetics (NASDAQ:GLYC) Research Coverage Started at StockNews.com - Defense World
GLYC Shares Experience Decline in Value - Knox Daily
GLYC’s Stock Dilemma: GlycoMimetics Inc’s Market Performance and Outlook - The InvestChronicle
Stocks of GlycoMimetics Inc (GLYC) are poised to climb above their peers - SETE News
GlycoMimetics Inc [GLYC] stock was sold by Invus Public Equities, L.P. at the price of US$50009.0 - Knox Daily
Balance Sheet Insights: GlycoMimetics Inc (GLYC)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - The Dwinnex
GlycoMimetics (NASDAQ:GLYC) Now Covered by Analysts at StockNews.com - Defense World
GlycoMimetics Inc [GLYC] 10% Owner makes an insider purchase of 260,873 shares worth 50009.0. - Knox Daily
GlycoMimetics Inc [GLYC] Is Currently 8.70 above its 200 Period Moving Avg: What Does This Mean? - The DBT News
Nothing is Better Than GlycoMimetics Inc (GLYC) stock at the moment - SETE News
GlycoMimetics Inc [GLYC] Investment Appeal on the Rise - Knoxdaily.com
GlycoMimetics Inc’s Bumpy Road: Analyzing the 52-Week Range and Future Prospects - The InvestChronicle
GlycoMimetics Inc (GLYC)’s Ratio Roundup: Key Metrics for Trailing Twelve Months - The Dwinnex
A stock that deserves closer examination: GlycoMimetics Inc (GLYC) - US Post News
StockNews.com Begins Coverage on GlycoMimetics (NASDAQ:GLYC) - Defense World
Analyzing GlycoMimetics (NASDAQ:GLYC) and Fulcrum Therapeutics (NASDAQ:FULC) - Defense World
Taking a look at what insiders are doing to gauge the GlycoMimetics Inc (GLYC)’s direction - Knox Daily
Vanguard Group Inc. Raises Stake in GlycoMimetics, Inc. (NASDAQ:GLYC) - Defense World
GlycoMimetics Inc (GLYC) Stock: A Year of Stock Market Dynamics - The InvestChronicle
GlycoMimetics Inc (GLYC) Performance and Fundamentals Dashboard tells a completely different story - SETE News
Apollomics Reports First Half 2024 Financial Results and Highlights Vebreltinib Clinical Progress - GlobeNewswire Inc.
Potential Price Increase for GlycoMimetics Inc (GLYC) After Recent Insider Activity - Knoxdaily.com
GlycoMimetics stock plunges to 52-week low of $0.17 By Investing.com - Investing.com Australia
It would be worthwhile to take a closer look at GlycoMimetics Inc (GLYC) - US Post News
GlycoMimetics stock plunges to 52-week low of $0.17 - Investing.com
GlycoMimetics stock plunges to 52-week low of $0.17 By Investing.com - Investing.com UK
Glycomimetics Inc Stock (GLYC) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):